Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

Presentation TCT 2024

TCT 235: Efficacy and Safety of Bivalirudin and Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients Who Underwent Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis

Presenter: Hamza Naveed

October 28, 2024

Presentation TCT 2023

TCT 215: Safety of Bivalirudin Versus Heparin in Patients With ST-elevation Myocardial Infarction: a Systematic Review and Meta-analysis:

Presenter: Mostafa Elbanna

October 26, 2023

Presentation TCT 2023

Bivalirudin Is the Most Evidence Based Antithrombin Agent for Primary PCI

Presenter: Gregg Stone

October 25, 2023

News Conference News TCT 2020

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

Shelley Wood

October 14, 2020

Presentation TCT 2020

Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin Versus Heparin in Acute Myocardial Infarction

Presenter: Gregg Stone

October 14, 2020

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

Presentation TCT 2018

The Case for Bivalirudin With Radial (and Femoral) Access

Presenter: John A. Bittl, C. Michael Gibson, Carey D. Kimmelstiel

September 23, 2018

Presentation TCT 2017

VALIDATE-SWEDEHEART NSTEMI: A Randomized Trial of Bivalirudin vs Heparin Monotherapy in Patients With NSTEMI

Presenter: Thomas F. Luscher, David Erlinge

October 31, 2017

Presentation TCT 2017

VALIDATE-SWEDEHEART STEMI: A Randomized Trial of Bivalirudin vs Heparin Monotherapy in Patients With STEMI

Presenter: Y. S. Chandrashekhar, David J. Moliterno, Stefan K. James

October 31, 2017

Presentation TCT 2017

Why I Prefer Bivalirudin for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, Uwe Zeymer

October 30, 2017

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

Do the Benefits of Bivalirudin Translate to Radial Intervention? Evidence From Randomized Trials

Presenter: A. Michael Lincoff, Franz-Josef Neumann, John A. Bittl

October 30, 2016

Presentation TCT 2016

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Harvey D. White

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Jorge F. Saucedo

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann

October 30, 2016

News Conference News TCT 2015

Cath Lab Economics: Pursuit of a Light at the End of the Tunnel

Nicole Lou

October 11, 2015

News Conference News TCT 2014

Meta-analysis: Less Bleeding, More Stent Thrombosis with Bivalirudin vs. Heparin After PCI

September 13, 2014

Advertisement

TCT 235: Efficacy and Safety of Bivalirudin and Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients Who Underwent Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis

TCT 215: Safety of Bivalirudin Versus Heparin in Patients With ST-elevation Myocardial Infarction: a Systematic Review and Meta-analysis:

Bivalirudin Is the Most Evidence Based Antithrombin Agent for Primary PCI

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin Versus Heparin in Acute Myocardial Infarction

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

The Case for Bivalirudin With Radial (and Femoral) Access

VALIDATE-SWEDEHEART NSTEMI: A Randomized Trial of Bivalirudin vs Heparin Monotherapy in Patients With NSTEMI

VALIDATE-SWEDEHEART STEMI: A Randomized Trial of Bivalirudin vs Heparin Monotherapy in Patients With STEMI

Why I Prefer Bivalirudin for Primary PCI in STEMI!

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Do the Benefits of Bivalirudin Translate to Radial Intervention? Evidence From Randomized Trials

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Cath Lab Economics: Pursuit of a Light at the End of the Tunnel

Meta-analysis: Less Bleeding, More Stent Thrombosis with Bivalirudin vs. Heparin After PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content